A summary of the 11th International Workshop on WM (iwWM) held October, 2022, has been published at https://link.springer.com/article/10.1007/s12254-023-00876-3. Click on the "Download PDF" box on the right.
Every two years, the International Workshop on WM (IWWM) brings together worldwide experts to share their latest understanding of the diagnosis and treatment of WM. It promotes "targeted research, clinical care methods, education, training, and advocacy for Waldenstrom’s macroglobulinemia". A report summarizing the presentations at the conference has been published, and is available at https://link.springer.com/article/10.1007/s12254-023-00876-3 -- click on the "Download PDF" box on the right. The chapters include summaries of presentations under the topics: New insights into BTKi treatment of Waldenström’s macroglobulinemia Management of WM patients previously exposed to BTK-inhibitors BTK inhibition in Waldenström’s macroglobulinemia: trial updates and biomarker analysis Emergent [...]
Partially funded by the WMFC and presented at ASH in December, 2022, this research identified three subtypes of WM. The full abstract that Dr. Hunter presented at ASH is available here. Two other WM-related abstracts using the multiomic analysis from Dr. Hunter’s research were also presented at ASH: An in-depth investigation into why epigenomic regulation is so important to MYD88 mutations is available here The data also has been applied to investigating why ibrutinib (and by extension other BTK inhibitors) may result in long Progression-Free Survival (PFS); that abstract is available here
Dr. Steve Treon of the Dana-Farber Cancer Institute presents a thorough summary of the latest knowledge of WM and its current and upcoming treatments. See https://youtu.be/JCrdW4VpNpw.
This journal article by a set of researchers from across Canada provides an overview of treatment options for WM, and their usage in current (2022) Canadian WM treatment. See https://www.mdpi.com/1718-7729/29/10/560.
Québec has become the first province to include financial coverage for any BTK inhibitor on its provincial drug formulary. This is excellent news for WMers in Québec. And we hope this will set an example for other provinces (although they are quite independent from one another in making such decisions). The announced coverage is for BeiGene's Brukinsa, or zanubrutinib. BeiGene's news release can be found here.
We often hear from the Bing Center for Waldenström's Macroglobulinemia at the Dana-Farber Cancer Institute (DFCI). Now let's hear from the Mayo Clinic. Dr. Morie Gertz has published "WM: 2023 Update on Diagnosis, Risk Stratification, and Management", available here. It provides an extensive overview of the literature covering : how WM is diagnosed the risk stratification for the disease the various treatment options (regimens) for WM No new research results are presented; the article is a summary of existing knowledge, and thus can be useful to those looking to refresh their knowledge about the various treatment options. Most useful to the [...]
Every year, the American Society of Hematology (ASH) conference is an opportunity for the latest hematology research from around the world to be presented. Although conference presentations do not go through peer review (unlike journal articles), they do provide an opportunity to see what is coming down the research pipeline. You can access 68 (!!) items that mention the word "macroglobulinemia" here. Of course, you may not want to look at all of them. So here are a very few, that we think may be of interest. First of all, we would be remiss if we did not point out the [...]
Thanks to an Educational Grant from BeiGene, we are very pleased to bring you two new, professionally-produced items: A Symptom Tracker: Available from our web page here, you can either print this out and write on it, or download it to your device and use it as a fillable form. This is designed for you to track symptoms that you may be aware of, physically; we're afraid you'll have to find your own way if you want to graph and track your blood test results. A new WMFC brochure: Available from a different web page, here. We will be distributing [...]
Breakthrough research by Dr. Zachary Hunter of the Dana-Farber Cancer Institute in Boston, funded by donations to the IWMF and the WMFC A much more detailed and nuanced understanding of the biology of Waldenstrom’s Macroglobulinemia has emerged from research funded by WMFC donors. The study by Dr. Zachary Hunter of the Dana-Farber Cancer Institute in Boston is a very sophisticated search for new research directions -- “Multiomic Analysis of DNA, RNA and Epigenomic Networks in WM”. To conduct a multiomic analysis Dr. Hunter’s research group combined a very broad range of data from various sources; clinical data, mutation studies, [...]
